6 news items
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
SLGL
28 May 24
approvals for our product candidates in our target markets, the potential delay in receiving such regulatory approvals and the possibility of adverse
HC Wainwright & Co. Reiterates Buy on Sol-Gel Technologies, Maintains $6 Price Target
SLGL
22 May 24
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Sol-Gel Technologies (NASDAQ:SLGL) with a Buy and maintains $6 price target.
HC Wainwright & Co. Maintains Buy on Sol-Gel Technologies, Lowers Price Target to $6
SLGL
20 May 24
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Sol-Gel Technologies (NASDAQ:SLGL) with a Buy and lowers the price target from $9 to $6.
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
SLGL
20 May 24
, declining 23% from Q4 2023. Patient refills in Q1 declined by 18% for the same time period. This is in part due to a targeted patient adherence campaign
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
SLGL
16 May 24
product candidates in our target markets, the potential delay in receiving such regulatory approvals and the possibility of adverse regulatory or legal
alwnzleycq2syzj6anvrp5dg3gprsiws49y5
SLGL
13 Mar 24
of recurring prescribers, with fourth-quarter patient refills increasing by 12%, driven by a targeted adherence campaign. In addition, TWYNEO increased its broad
- Prev
- 1
- Next